Today in Biology — Oct 7

[SOFIA] Welcome back to The Dish! Today in Biology, we're diving straight into some big shifts in how science gets done, and especially how it gets funded. And I think the headline here has to be the Genesis Mission.

[DANIEL] Agreed. The Department of Energy’s Genesis Mission framework, just released, is a pretty clear signal about where a lot of national-level resources are headed. It's explicitly focused on AI-accelerated breakthroughs in science and engineering.

[SOFIA] Exactly! And it’s not just theoretical. The "Science Signal" from the Office of the Under Secretary for Science highlighted September as really seeing the *impact* of Genesis expanding. It’s moving from "potential to practice" is their phrase, especially for AI-enabled science and engineering. For us, that means if you're working on molecular tools, or trying to engineer new pathways in non-model organisms, AI is no longer just a nice-to-have. It's becoming central to the national strategy.

[DANIEL] And the Genesis report itself, from the Office of Science Advisory Committee, specifically examines AI's role in both fusion and biological design. So, that's not just a general AI push; it's a targeted one that includes biology, which is a pretty strong indicator for where the DOE sees future growth and investment. We’re talking about using AI to design new proteins, predict interactions, optimize metabolic pathways—things that directly feed into engineering biology.

[SOFIA] So, for folks in the labs right now, thinking about their next grant, or even their next project, this is a huge flag to integrate AI into your experimental design, your data analysis, even your hypothesis generation. Because that's where the DOE is putting its weight.

[DANIEL] It’s also interesting to see the funding landscape shifting in other areas. We’ve got the NIH announcing over $237 million for High-Risk, High-Reward research. That sounds great on the surface—bold biomedical and behavioral research. But then you look at what's happening over at the NSF.

[SOFIA] Yeah, that was a bit of a surprise. The National Science Foundation ended its fiscal year with over a billion dollars unspent. A *billion*. And that's after a pretty sharp slowdown in grantmaking.

[DANIEL] It raises questions about where the bottlenecks are, doesn't it? Is it a lack of quality proposals? Or a systemic issue in how funds are being allocated and processed? For scientists trying to secure grants, seeing that much money left on the table at a major funding body is… concerning. It suggests a potential disconnect between the available funds and the ability to distribute them effectively.

[SOFIA] Right, especially when other initiatives are trying to push the envelope. Like ARPA-H launching programs to modernize clinical trials. That's a huge deal for getting engineered biological solutions, like new therapies or diagnostics, out of the lab and into patients. They're looking at trial design, site activation, consent, patient data collection—all the parts that can bog down translational work.

[DANIEL] And that's a critical area. Clinical trials are often the most expensive and time-consuming bottleneck in bringing new biological technologies to market. Any initiative that can genuinely streamline that process could have a massive impact on the pace of innovation. The devil will be in the details, of course, regarding how these new programs are structured and if they can overcome the inherent complexities of human trials.

[SOFIA] Absolutely. So, we have this strong push from the DOE on AI in biology, a significant investment in high-risk, high-reward from NIH, but a puzzling slowdown at NSF, and ARPA-H tackling the translational pipeline. It really paints a picture of a field being actively reshaped by national priorities and funding shifts. The message seems pretty clear: if you’re building tools for biology, think AI, think big, and think about getting it into the real world.